Stryker Corp Stock Price, News & Analysis

Stryker (NYSE: SYK) unveiled significant advancements in its Mako SmartRobotics™ technology at AAOS 2025 Annual Meeting in San Diego. The company highlighted that Mako has achieved over 1.5 million procedures globally across 45 countries.

Key announcements include:

• Introduction of Mako Total Hip with Advanced Primary and Revision, featuring first-to-market robotic hip revision capability
• Launch of fourth-generation Mako 4 system, offering multiple applications across Total Hip, Total Knee, Partial Knee and Spine procedures
• Integration of fourth-generation Q Guidance System
• Expansion into Mako Spine and Mako Shoulder applications

The company completed initial Mako Spine cases in October and plans full U.S. commercial launch in second half of 2025. Mako Shoulder, introduced late last year, remains in market release through 2025.

Inari Medical, now part of Stryker (NYSE: SYK), has launched the Artix™ Thrombectomy System, a new medical device designed for peripheral arterial thrombectomy. The system combines aspiration and mechanical thrombectomy capabilities to address arterial blood clots in the legs, which are life- and limb-threatening emergencies.

The Artix system features a dual mechanical thrombectomy and aspiration toolkit, capable of removing acute to chronic clots in a single session. It includes an 8 Fr. low-profile sheath available in 65cm and 90cm lengths, and an innovative over-the-wire mechanical element. The system also incorporates a covered nitinol mesh funnel to minimize clot migration risk.

The first commercial case using Artix was performed by Dr. Jonathan Bowman at Norwalk Hospital on October 19, 2024. The device aims to overcome limitations of existing therapies, which can lead to ineffective clot retrieval, significant blood loss, vessel trauma, and high rates of lytic use.

Stryker (NYSE:SYK) has launched its latest personal protective equipment, the Steri-Shield 8 personal protection system. The new system features a customizable helmet with three points of contact and three toga choices, representing an evolution in healthcare PPE technology.

Key improvements include a helmet with three points of securement, a ponytail accommodation path, enhanced visibility with a brighter light and 22% wider field of vision compared to previous versions. The system also features a redesigned fan targeting the front and back of users' necks, a sleeker battery, and a more efficient charging station.

The three toga styles offer AAMI level 4 (2012) protection in all critical zones, providing maximum fluid and microbial barrier protection for healthcare professionals.

Stryker (NYSE:SYK) has launched the Sync Badge, a hands-free wearable communication device designed to enhance collaboration in patient care environments. The device allows care team members to use voice commands to connect with colleagues across units and roles.

Key features include:

• Voice activation using 'Okay Vocera' wake word
• Dedicated panic button for emergency assistance
• Do Not Disturb mode with urgent call breakthrough
• Integration with EHR, nurse call systems, and medical devices

The launch aims to address ongoing nursing shortages and unpredictable healthcare environments by simplifying workflows and improving communication efficiency.

Stryker (NYSE: SYK) has completed the acquisition of Inari Medical, a company specializing in venous thromboembolism (VTE) clot removal solutions. The acquisition provides Stryker entry into the fast-growing peripheral vascular segment. The transaction was completed through a cash tender offer at $80.00 per share, with approximately 81.69% (48,504,444 shares) of Inari's outstanding shares validly tendered.

Inari's product portfolio, which includes the FlowTriever System for pulmonary embolism treatment and the ClotTriever System for peripheral vessel thrombectomy, complements Stryker's Neurovascular business. Following the merger completion on February 19, 2025, Inari has become a wholly owned subsidiary of Stryker and will be delisted from the Nasdaq Global Select Market.

Stryker (NYSE:SYK) has announced its participation in Citi's 2025 Unplugged Medtech and Life Sciences Access Day. The event will take place on Thursday, February 27, 2025 at Citigroup Headquarters in New York.

The company's management will deliver a presentation scheduled for 12:15 p.m. Eastern Time. Investors and interested parties can access a simultaneous webcast of the presentation through Stryker's website. The presentation will also be archived on the company's Investor Relations page for future reference.

Stryker (NYSE:SYK) announced that Allan Golston will not seek re-election at the company's 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025. Golston served on Stryker's Board of Directors for 14 years since 2011, including roles as independent Lead Director (2016-2022), and positions on the Governance and Nominating Committee, while also chairing the Compensation and Human Capital and Audit Committees.

Golston, who has been President of the United States Program at the Bill & Melinda Gates Foundation since 2006, brought extensive healthcare industry experience to Stryker's board. His background includes positions as a certified public accountant and hospital finance executive. He also serves as a director at Harley-Davidson.

Stryker (NYSE:SYK) has announced its Board of Directors' declaration of a quarterly dividend of $0.84 per share. The dividend will be payable on April 30, 2025, to shareholders of record as of the close of business on March 31, 2025. This dividend represents a 5.0% increase compared to the prior year while remaining unchanged from the previous quarter.

RevBio has been granted its 10th U.S. patent (12,178,937) for the TETRANITE® bone adhesive technology, expanding protection for injectable mineral-organic structural bone adhesive compositions containing alpha tricalcium phosphate. This complements their existing patent 11,638,777 for bone fracture repair methods.

TETRANITE® is notable as the only patented bone adhesive containing phosphoserine, an organic compound linked to bone regeneration. RevBio acquired exclusive worldwide patent rights from Stryker (NYSE: SYK) for six patent families, providing protection through 2033. Since 2016, RevBio has filed fourteen Patent Cooperation Treaty applications, with protection extending to 2043 across multiple jurisdictions including the U.S., EU, Canada, Australia, Japan, and China.